Evidence map›Paper›PMID 38826290›Full record

ArticlebioRxiv : the preprint server for biology2024

Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread.

Felix Pahmeier, Stephanie R Monticelli, Xinyi Feng, Christy K Hjorth, Albert Wang, Ana I Kuehne, Russell R Bakken, Thomas G Batchelor, Saeyoung E Lee, Marissa Middlecamp and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Felix Pahmeier *Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-7445-2259
Stephanie R Monticelli *Viral Immunology Branch, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.ORCID 0000-0002-5031-2534
Xinyi FengDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Christy K HjorthDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0003-2324-8984
Albert WangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Ana I KuehneViral Immunology Branch, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Russell R BakkenViral Immunology Branch, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Thomas G BatchelorViral Immunology Branch, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Saeyoung E LeeDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Marissa MiddlecampMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Lauren StuartMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Dafna M AbelsonMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Scott B BieringDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0003-1991-629X
Andrew S HerbertViral Immunology Branch, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0003-0232-7077
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-7238-4037

Funding

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral ThreatsU19AI142777 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHANDRAN, KARTIK · 2019 to 2023
$21.9M
Medical Scientist Training ProgramT32GM149364 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Myles H. Akabas · 2023 to 2026
$7.5M
Host factors and viral determinants mediating flavivirus NS1 tissue-specific endothelial dysfunction and vascular leakR01AI168003 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2022 to 2026
$3.2M
Structure-based Vaccine Design for CCHFVR01AI152246 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CHANDRAN, KARTIK, MCLELLAN, JASON SCOTT · 2020 to 2024
$2.2M
NIAID NIH HHS R01 AI152246NIAID NIH HHS R01 AI168003NIAID NIH HHS U19 AI142777NIGMS NIH HHS T32 GM149364
6 · The paper itself

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is a priority pathogen transmitted by tick bites, with no vaccines or specific therapeutics approved to date. Severe disease manifestations include hemorrhage, endothelial dysfunction, and multiorgan failure. Infected cells secrete the viral glycoprotein GP38, whose extracellular function is presently unknown. GP38 is considered an important target for vaccine and therapeutic design as GP38-specific antibodies can protect against severe disease in animal models, albeit through a currently unknown mechanism of action. Here, we show that GP38 induces endothelial barrier dysfunction

Identifiers

PMID38826290
PMCPMC11142176

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.